Evidence map›Paper›PMID 38394385›Full record

ArticleThe oncologist2024

Adherence to Treatment and Follow-Up of Precancerous Cervical Lesions in Ethiopia.

Clara Yolanda Stroetmann, Muluken Gizaw, Rahel Alemayehu, Abigiya Wondimagegnehu, Friedemann Rabe, Pablo Santos, Bariki Mchome, Blandina Theophil Mmbaga, Adamu Addissie, Eva Johanna Kantelhardt

Abstract read
In one paragraph

Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clara Yolanda StroetmannGlobal Health Working Group, Institute for Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.ORCID 0009-0005-4256-2612
Muluken GizawGlobal Health Working Group, Institute for Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Rahel AlemayehuDepartment of Preventive Medicine, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.
Abigiya WondimagegnehuGlobal Health Working Group, Institute for Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.ORCID 0000-0002-1491-0959
Friedemann RabeGlobal Health Working Group, Institute for Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Pablo SantosGlobal Health Working Group, Institute for Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Bariki MchomeKilimanjaro Christian Medical Centre, Moshi, Tanzania.
Blandina Theophil MmbagaKilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre and Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Adamu AddissieGlobal Health Working Group, Institute for Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Eva Johanna KantelhardtGlobal Health Working Group, Institute for Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.ORCID 0000-0001-7935-719X

Funding

Else Kroener-Fresenius-Foundation 2018_HA31SPGerman Ministry of Research and Education 01KA2220B
6 · The paper itself

Abstract

backgroundIn Ethiopia, both incidence and mortality of cervical cancer are relatively high. Screening services, which were implemented during the past few years, are currently being expanded. The World Health Organization recommends patients with a positive VIA (visual inspection with acetic acid) result should immediately receive treatment followed by rescreening after 1 year as precancerous lesions can reoccur or become residential despite treatment. MATERIALS AND

methodsScreening logbooks dating between 2017 and 2020 were retrospectively reviewed in 14 health facilities of Addis Ababa and Oromia region. Data for 741 women with a VIA-positive result were extracted and those women were asked to participate in a questionnaire-based phone interview to gain insights about adherence to treatment and follow-up. Data were analyzed using descriptive methods and then fitted into 2 generalized linear models to test variables for an influence on adherence to follow up.

resultsAround 13 800 women had received a VIA screening, of which approximately 820 (5.9%) were VIA positive. While over 90% of women with a positive screen received treatment, only about half of the treated patients returned for a follow-up examination. After treatment, 31 women had a VIA-positive re-screen. We found that educational status, age over 40, no/incorrect follow-up appointment, health facility-related barriers, and use of reminders are important drivers of adherence to follow up.

conclusionOur results revealed that adherence to treatment after VIA positive screening is relatively high whereas adherence to follow up recommendations still needs improvement. Reminders like appointment cards and phone calls can effectively reduce the loss of follow-up.

Indexed as

Precancerous ConditionsUterine Cervical NeoplasmsAdultAgedEarly Detection of CancerEthiopiaFemaleFollow-Up StudiesHumansMiddle AgedPatient ComplianceRetrospective StudiesYoung Adultadherencecervical cancer screeningcryotherapyfollow-upprecancerous lesionsrecurrence

Identifiers

PMID38394385
PMCPMC11067800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.